Biopsies
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 7 |
97. 潰瘍性大腸炎
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
Showing 1 to 7 of 7 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04272307 (ClinicalTrials.gov) | May 14, 202020200514 | 14/2/202020200214 | MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach. MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy ... | MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach. MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy ... | Inflammatory Bowel Diseases;Colitis;Ulcerative | Biological: Blood samples;Procedure: Stool samples;Procedure: Colorectal biopsies | University Hospital, Bordeaux | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | 18 Years | N/A | All | 40 | France | |
| 2 | EUCTR2018-004890-28-IT (EUCTR) | 09/10/201920191009 | 07/10/202020201007 | Study for the research of predictive factors of response to Tofacitinib therapy in patients with ulcerative rectal colitis. Study for the research of predictive factors of response to Tofacitinib therapy in patients with ulc ... | (A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsies from (A)ctive ulcerative colitis patients to predict clinical (R)esponse (the AVATAR study). - AVATAR (A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsiesfrom (A)ctive ... | Ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 10045282;Term: UC;System Orga ... | Trade Name: Xeljanz Product Name: Xeljanz Product Code: [N/A] | DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 4 | Italy | ||
| 3 | EUCTR2019-001032-54-FR (EUCTR) | 23/07/201920190723 | 19/06/201920190619 | Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with or without antiviral therapy Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative ... | Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with or without antiviral therapy - CYTOVEDO Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative ... | Patient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 1 and 2 biopsies of the inflammatory tissue and presence of a CMV infection in the inflammatory tissue objectified by a viral load greater than 5 IU / 100000 cells by qPCR. MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 MedDRA version: 20.1;Classification code 10058881;Term: Cytomegalovirus viremia;System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Patient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an ... | Trade Name: valganciclovir Product Name: valganciclovir Trade Name: vedolizumab Product Name: vedolizumab Trade Name: valganciclovir Product Name: valganciclovir Trade Name: vedolizumab Product Name: vedolizum ... | CHU de Saint Etienne | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 4 | France | ||
| 4 | NCT04030676 (ClinicalTrials.gov) | July 17, 201920190717 | 19/7/201920190719 | QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Coliti ... | Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC) Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation Du ... | Cytomegalovirus Infections | Procedure: Biopsies;Biological: Blood samples | Centre Hospitalier Universitaire de Saint Etienne | NULL | Recruiting | 18 Years | N/A | All | 196 | N/A | France |
| 5 | NCT03172195 (ClinicalTrials.gov) | October 11, 201720171011 | 23/5/201720170523 | Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colit ... | Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colit ... | Colitis, Ulcerative | Procedure: rectosigmoidoscopy;Biological: biopsies;Biological: blood sample | Centre Hospitalier Universitaire de Saint Etienne | NULL | Recruiting | 18 Years | N/A | All | 100 | N/A | France |
| 6 | ChiCTR1900023689 | 2012-03-0120120301 | 2019-06-0720190607 | Comparison of white light endoscopy vs chromoendoscopy in the detection rate of dysplasia and colorectal cancer in ulcerative colitis: A Multicenter Long-term Follow-up Randomized Controlled Trial in China Comparison of white light endoscopy vs chromoendoscopy in the detection rate of dysplasia and colore ... | Comparison of white light endoscopy vs chromoendoscopy in the detection rate of dysplasia and colorectal cancer in ulcerative colitis: A Multicenter Long-term Follow-up Randomized Controlled Trial in China Comparison of white light endoscopy vs chromoendoscopy in the detection rate of dysplasia and colore ... | Ulcerative colitis | Gold Standard:Pathological examination;Index test:1. targeted biopsies were taken from all visible lesions when using white light endoscopy 2. using white light endoscopy, sequential 4-quadrantic random biopsies were taken at every 10-cm intervals colon from disease segments defined by the endoscopist in addition to targeted biopsies from all visible lesions; 3. tar; Gold Standard:Pathological examination;Index test:1. targeted biopsieswere taken from all visible le ... | Xijing Hospital of Digestive Diseases, Fourth Military Medical University | NULL | Completed | 18 | 70 | Both | Target condition:141;Difficult condition:0 | N/A | China |
| 7 | EUCTR2009-013890-16-PT (EUCTR) | 28/05/201020100528 | 21/12/200920091221 | Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients - Herica Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to ... | Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients - Herica Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to ... | This national, multi-centre, open-label pilot study will assess the histologic remission in patients with moderate to severe active ulcerative colitis under infliximab treatment who have had an inadequate response to conventional therapy.Biopsies will be analyzed throughout the study in order to assess histological disease modifying effects in those patients. MedDRA version: 16.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 This national, multi-centre, open-label pilot study will assess the histologic remission in patients ... | Trade Name: Remicade Product Name: Remicade | GEDII - Grupo de Estudo da Doença inflamatória Intestinal | NULL | Not Recruiting | Female: yes Male: yes | 20 | Portugal |